NFKB1 and neoplasm: While emerging evidence from non-thyroid cancers implicates microbiota-driven pathways (e.g., Wnt/β-catenin, TLR/NF-κB) in tumor progression and therapy resistance, direct experimental validation in thyroid cancer models is lacking.